CLINICAL TRIALS PROFILE FOR ZOLOFT
✉ Email this page to a colleague
All Clinical Trials for ZOLOFT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000440 ↗ | Sertraline and Naltrexone for Alcohol Dependence | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 1969-12-31 | This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia). |
| NCT00000446 ↗ | Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 1969-12-31 | This study will investigate the use of sertraline (Zoloft) to decrease alcohol consumption and crime-related post-traumatic stress disorder in those individuals with both disorders. This will be a 12-week, placebo-controlled, double-blind outpatient trial. All subjects will receive cognitive behavioral therapy in addition to a placebo or sertraline. Comprehensive evaluation will be done at study entry; treatment termination; and 6, 9, and 12 months after study entry. |
| NCT00000451 ↗ | Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline) | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2003-01-01 | This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study. |
| NCT00000451 ↗ | Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline) | Completed | Yale University | Phase 2 | 2003-01-01 | This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study. |
| NCT00000458 ↗ | Sertraline and Cognitive Therapy in Depressed Alcoholics | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 1969-12-31 | This study will assess whether individuals treated with sertraline (Zoloft) and cognitive behavior therapy will experience improvement with their depression and consume less alcohol than individuals treated with a placebo and cognitive behavior therapy. This is a 12-week, random assignment, placebo-controlled, double-blind study with followup assessments 1 and 3 months after treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZOLOFT
Condition Name
Clinical Trial Locations for ZOLOFT
Trials by Country
Clinical Trial Progress for ZOLOFT
Clinical Trial Phase
Clinical Trial Sponsors for ZOLOFT
Sponsor Name
